Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin
Open Access
- 15 July 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (2) , 215-222
- https://doi.org/10.1086/505204
Abstract
Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significKeywords
This publication has 27 references indexed in Scilit:
- A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal CandidiasisClinical Infectious Diseases, 2004
- Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and CandidemiaAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of Anidulafungin against Selected Clinically Important Mold IsolatesAntimicrobial Agents and Chemotherapy, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus sppDiagnostic Microbiology and Infectious Disease, 2003
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal CandidiasisAntimicrobial Agents and Chemotherapy, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven AspergillosisClinical Infectious Diseases, 1999
- Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.Diagnostic Microbiology and Infectious Disease, 1996